tbuckley/cabot-search huggingface dataset:
Abstract 13972: Dexmedetomidine Ameliorates Monocrotaline Induced Pulmonary Arterial Hypertension in Rats
Authors: Yusuke Kajikawa, Susumu Hosokawa, Kenji Wakabayashi, Yasuhiro Maejima, Mitsuaki Isobe, Shouzaburoh Doi
Journal: Circulation (2015)

[Introduction] Pulmonary arterial hypertension (PAH) is characterized by increased proliferation and apoptosis resistance of pulmonary arterial smooth muscle cells (PASMCs). Dexmedetomidine (DEX) is a selective α2-aderenergic receptor agonist that is used for sedation in clinical practice. It has been reported that DEX inhibits inflammatory responses through cytokines, such as TNF-alpha, IL-6. Furthermore other reports show that G-protein-coupled receptors (GPCRs) are regulated by β-arrestins, which are also involved with inflammation. [Hypothesis] DEX ameliorates monocrotaline (MCT)-induced PAH in rats by its anti-inflammatory effect. [Methods] We treated 6 weeks-old male Sprague-Dawley rats with a single 60mg/kg intraperitoneal injection of MCT. After 14 days of injection, one group of rats was started to administer dexmedetomidine (dose: 2μg/kg/hour, MCT+DEX group) continuously using osmotic pumps, the other group was not treated with DEX (MCT group). We performed physiological examination and cardiac catheterization to measure right ventricular systolic pressure (RVSP) at day 23. [Results] Both RVSP and survival rate of rats in MCT+DEX group markedly improved compared with those in MCT group (RVSP; 38mmHg±11mmHg vs 91mmHg±6mmHg, survival rate; 42% vs 0% at day 30). In histological analysis, DEX reduced the medial hypertrophy of pulmonary arterioles, and decreased phosphorylated-NF-kB p65 (p-p65) positive PASMCs in MCT+DEX group compared with those of MCT group. In addition, DEX suppressed PASMCs proliferation with PCNA staining, and induced apoptosis of PASMCs with TUNEL assay. Then we examined the involvement of β-arrestins in PAH. It showed that βarrestin1 expressions reduced in MCT group compared with that of MCT+DEX group with western blotting and immunohistochemistry. However β-arrestin2 expressions had no significant difference between the two groups. [Conclusions] DEX ameliorates MCT-induced PAH in rats, one of the mechanism of which may be NF-kB inhibition through β-arrestin1. DEX can be a new therapeutic tool for PAH.
Adherence to screening colonoscopy and its influencing factors in China: a multicentre population-based cross-sectional study
Authors: Hong-Da Chen, Ni Li, Jian-Song Ren, Yue-Ming Zhang, Shuang-Mei Zou, Zhao-Xu Zheng, Ju-Fang Shi, Kai Zhang, Jie He, Min Dai
Journal: The Lancet (2017)
Severe mental disorders in rural China: a longitudinal survey
Authors: Mao-Sheng Ran, Xue Weng, Yu-Jun Liu, Tian-Ming Zhang, Graham Thornicroft, Larry Davidson, Cheryl H.K. Chui, Shi-Hui Hu, Xin Yang, Fu-Rong Lin, Chang-Cheng Liu, Bo Liu, Eric Yu-Hai Chen, Cecilia Lai-Wan Chan, Wei-Hong Kuang, Meng-Ze Xiang
Journal: The Lancet (2017)
Updated Results of a Randomized Phase II Trial of Idarubicin and Cytarabine with Clofarabine or Fludarabine in Patients with Newly Diagnosed Acute Myeloid Leukemia
Authors: Nicholas J. Short, Farhad Ravandi, Xuelin Huang, Jorge E. Cortes, Naveen Pemmaraju, Naval Daver, Rita B. Khouri, Gautam Borthakur, Nitin Jain, Marina Konopleva, Zeev Estrov, Guillermo Garcia-Manero, Tapan M. Kadia, William G. Wierda, Courtney D DiNardo, Susan M. O'Brien, Syed Shah, Allison Pike, Mark Brandt, Hagop M. Kantarjian, Elias J. Jabbour
Journal: Blood (2016)
Quality and Safety in Health Care, Part XXXIV
Authors: Jay A. Harolds
Journal: Clinical Nuclear Medicine (2017)

The PINNACLE (Practice INNovation And Clinical Excellence) program was started in 2008 by the American College of Cardiology and its National Cardiovascular Data Registry. This was the first and now the largest countrywide prospective registry to improve care quality for cardiac outpatients. The registry focuses on reporting about the adherence to guidelines in treating individuals with high blood pressure, atrial fibrillation, coronary artery disease, and/or cardiac failure.
Chest computed tomography-derived low fat-free mass index and mortality in COPD
Authors: Merry-Lynn N. McDonald, Alejandro A. Diaz, Erica Rutten, Sharon M. Lutz, Rola Harmouche, Raul San Jose Estepar, Greg Kinney, John E. Hokanson, Barbara A. Gower, Emiel F.M. Wouters, Stephen I. Rennard, Craig P. Hersh, Richard Casaburi, Mark T. Dransfield, Edwin K. Silverman, George R. Washko
Journal: European Respiratory Journal (2017)

Low fat-free mass index (FFMI) is an independent risk factor for mortality in chronic obstructive pulmonary disease (COPD) not typically measured during routine care. In the present study, we aimed to derive fat-free mass from the pectoralis muscle area (FFM PMA ) and assess whether low FFMI PMA is associated with all-cause mortality in COPD cases. We used data from two independent COPD cohorts, ECLIPSE and COPDGene. Two equal sized groups of COPD cases (n=759) from the ECLIPSE study were used to derive and validate an equation to calculate the FFM PMA measured using bioelectrical impedance from PMA. We then applied the equation in COPD cases (n=3121) from the COPDGene cohort, and assessed survival. Low FFMI PMA was defined, using the Schols classification (FFMI &lt;16 in men, FFMI &lt;15 in women) and the fifth percentile normative values of FFMI from the UK Biobank. The final regression model included PMA, weight, sex and height, and had an adjusted R 2 of 0.92 with fat-free mass (FFM) as the outcome. In the test group, the correlation between FFM PMA and FFM remained high (Pearson correlation=0.97). In COPDGene, COPD cases with a low FFMI PMA had an increased risk of death (HR 1.6, p&lt;0.001). We demonstrated COPD cases with a low FFMI PMA have an increased risk of death.
Mutation Profiling by Targeted Next-Generation Sequencing for Diagnostics and Patient Cohort Screening in FFPE NSCLC Samples
Authors: Linnea La Fleur, Lotte Moens, Elin Falk-Sörqvist, Magnus Sundström, Johanna S. M. Mattsson, Hirsh Koyi, Eva Branden, Hans Brunnström, Simon Ekman, Martin Sandelin, Johan Isaksson, Karin Jirström, Patrick Micke, Mats Nilsson, Johan Botling
Journal: Journal of Thoracic Oncology (2015)
PTU-090 Echocardiography in patients with cirrhosis does not predict the clinical outcome after transjugular intrahepatic portosystemic stent-shunt (tipss)
Authors: F Gohar, MJ Armstrong
Journal: Gut (2017)

Introduction  TIPSS is widely used to treat refractory ascites and variceal haemorrhage. Cardiac dysfunction is frequently observed in patients with cirrhosis. However, there remains a paucity of data from routine clinical practice regarding the use of echocardiography in the pre-assessment of TIPSS.  Aim  To investigate if echocardiography predicts outcomes post-TIPSS in patients with cirrhosis.  Method  Patients who underwent echocardiography and TIPSS at the liver transplant centre (Birmingham, UK) between 1999–2016 were included. All echocardiography measures [left ventricle (LV) ejection fraction (EF); LV diastolic diameter (LVDD); LV systolic diameter (LVSD); early maximal ventricular filling velocity/late filling velocity (E/A) ratio, deceleration time (DT), diastolic dysfunction as per ASE/BSE guidelines; regional wall abnormality) were independently reviewed/graded by a senior cardiologist (RS). Clinical predictors of 30 day, 90 day and overall transplant free-survival were assessed.  Results  117 patients with cirrhosis (median age 56 years; 54% alcohol; CPB/C 71/14.5%) underwent TIPSS for ascites (n=78) and variceal haemorrhage (n=39). Median MELD and UKELD was 12 (IQR 9–17) and 53 (IQR 50–57), respectively. Median post-TIPSS portal pressure gradient was 8 (IQR 6–10) mmHg. Post-TIPSS complications (  30 day, 90 day and overall transplant-free survival was 90% (n=105), 80% (n=93), and 31% (n=36) over a median 663 (IQR 385–2368) days follow-up. MELD (p /=15 had an AUROC 0.855 (95% CI 0.74–0.98) for 30 day transplant free-survival.  6% (n=7) of patients pre-TIPSS had a history of IHD and 34% (n=40) had 1 or more CVD risk factors. 50% (n=59) had a normal echocardiography, 33% (n=39) had grade 1–3 LV diastolic dysfunction and 6% (n=7) had LVEF  Conclusion  Echocardiography in patients with cirrhosis does not predict post-TIPSS survival. MELD score remains the best predictor of early and late mortality post-TIPSS.  Disclosure of Interest  None Declared
Longitudinal performance of self-collected human papilloma virus testing and other mainstream strategies in detecting prevalent and incident cervical precancer: a 15-year cohort study in china
Authors: Xiao-Qian Xu, Li Zhang, Shang-Ying Hu, Feng Chen, Xun Zhang, Qin-Jing Pan, Wen-Hua Zhang, Rui-Mei Feng, Li Dong, Qian Zhang, Jun-Fei Ma, Catherine Sauvaget, Fang-hui Zhao, You-Lin Qiao, Rengaswamy Sankaranarayanan
Journal: The Lancet (2017)
IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma
Authors: M. Miller, U. Sahin, E. Derhovanessian, B-P Kloke, P. Simon, V. Bukur, C. Albrecht, A. Paruzynski, M. Löwer, A. Kuhn, K. Schreeb, S. Attig, A Kemmer Brueck, S. Bolte, S. Grabbe, C. Höller, J. Utikal, C. Huber, C. Loquai, Ö Türeci
Journal: Annals of Oncology (2017)
NHS pays £45 000 to family of a woman who was kept alive against her will
Authors: Clare Dyer
Journal: BMJ (2017)

The family of a stroke victim who was kept alive for nearly two years against her will have received a £45 000 pay out from the NHS in an out-of-court settlement.

Brenda Grant, 81, had a stroke in October 2012 which left her unable to walk, talk, or swallow. Without telling her family, she had made a living will, …
Incidence of Bleeding Events in Acute Myeloid Leukemia (AML) Patients Receiving Anticoagulation Therapy for Treatment of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE) Who Are Also Undergoing Induction or Re-Induction Therapy
Authors: Meagan Scott, Maho Hibino, Marie Cavalier, Bayard L. Powell, Dianna S. Howard, Leslie Renee Ellis, Rupali Bhave, Susan Lyerly, Megan Manuel, Sarah Dralle, Timothy S Pardee
Journal: Blood (2017)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Authors: Antoni Torres, Nanshan Zhong, Jan Pachl, Jean-François Timsit, Marin Kollef, Zhangjing Chen, Jie Song, Dianna Taylor, Peter J Laud, Gregory G Stone, Joseph W Chow
Journal: The Lancet Infectious Diseases (2017)
Cold atmospheric plasma (CAP), a novel physicochemical source, induces neural differentiation through cross-talk between the specific RONS cascade and Trk/Ras/ERK signaling pathway
Authors: Ja-Young Jang, Young June Hong, Junsup Lim, Jin Sung Choi, Eun Ha Choi, Seongman Kang, Hyangshuk Rhim
Journal: Biomaterials (2017)
Abstract 14958: Long-term Treatment With Tadalafil and Hydroxychloroquine Combination Protects Aging Obese Mice Against Myocardial Ischemia/Reperfusion Injury via Down-regulating MicroRNA103
Authors: Rui Wang, Lei Xi, Rakesh C Kukreja
Journal: Circulation (2017)

Introduction: Obesity is one of the most prevalent health issues in U.S. Nearly 35% of American adults are overweight with increased risk of having heart diseases. Studies show that microRNA 103 (m...
Evidence-Based Therapy and Its Association With Workforce Detachment After First Hospitalization for Heart Failure
Authors: Rasmus Rørth, Emil L. Fosbøl, Ulrik M. Mogensen, Kristian Kragholm, Pardeep S. Jhund, Mark C. Petrie, Morten Schou, Gunnar H. Gislason, John J.V. McMurray, Christian Torp-Pedersen, Lars Køber, Søren L. Kristensen
Journal: JACC Heart Failure (2017)
Prevalence of skin disease in a population-based sample of adults from five European countries
Authors: A. Svensson, R.F. Ofenloch, M. Bruze, L. Naldi, S. Cazzaniga, P. Elsner, M. Goncalo, M.-L.A. Schuttelaar, T.L Diepgen
Journal: British Journal of Dermatology (2017)

There is a lack of prevalence data on skin diseases in the general adult population; most studies have been carried out in small, national or consecutive clinical samples.To determine the prevalence of common skin disease in the general European population and to assess differences in the characteristics of treatment between countries.A random sample consisting of 12 377 participants aged 18-74 years was drawn from the general population of five European countries (Germany, Italy, the Netherlands, Portugal and Sweden). This was a cross-sectional study and all participants were interviewed using a standardized questionnaire that assessed the occurrence of 10 common skin diseases during lifetime, past year and past month. If a skin disease was reported, we additionally assessed who performed the diagnosis and treatment, and whether drugs had been prescribed.The most common skin disease was warts (41·3%), followed by acne (19·2%) and contact dermatitis (15·0%). In general, women were more often affected by skin diseases compared with men; only skin cancer had a slightly higher prevalence in men. The prevalence of skin diseases in northern countries (Germany, the Netherlands and Sweden) was generally higher than in the southern countries (Italy and Portugal). In the Netherlands the treatment of skin diseases was less often performed by a dermatologist compared with the other countries.The prevalence estimates reported in this study are derived from a representative sample of the general population. Data assessment was performed comprehensively across countries, thus country-specific prevalence estimates are comparable.
Curcumin inhibits cell proliferation, invasion and migration in U2OS human osteosarcoma cells
Authors: Pay Chin Leow, Zheng Yang, Pui Lai Rachel Ee
Journal: Cancer Research (2008)

1200  Osteosarcoma is the most common primary malignancy of the bone in which the mechanism of disease progression is poorly understood. Despite intensive chemotherapy and surgical resection, osteosarcoma has a high tendency to metastasize. There is clearly a need to identify new therapeutic agents in order to improve the outcome for osteosarcoma patients. Curcumin, a dietary pigment found in the spice tumeric, has recently been shown to exhibit anti-invasive and anti-metastatic properties in several human cancers, but its effect in osteosarcoma has yet to be explored. The purpose of this study is, therefore, to investigate the potential role of curcumin in inhibiting cell proliferation, invasion and migration in osteosarcoma. Using MTT assays, we found that curcumin suppressed the proliferation of U2OS cells in a concentration-dependent manner (IC50 19.9 µM, 72 hours). In addition, Matrigel invasion assays showed that curcumin treatment significantly reduced the invasive capacity of U2OS cells by 29% at 5μM and 77.3% at 10μM. In parallel, wound healing assays showed that curcumin drastically suppressed the rate of U2OS cell migration. As emerging evidence implicate the involvement of the Wnt/s-catenin pathway in osteosarcoma disease progression, we further assessed whether curcumin could regulate β-catenin/Tcf transcriptional activation by using a reporter gene (TOPglow) containing four copies of the Tcf-binding site in U2OS cells. Curcumin decreased TOPglow activity without affecting the negative control FOPglow in a dose-dependent fashion, indicating an inhibition of downstream transcriptional activity of the s-catenin/Tcf complex. In summary, our data suggest that curcumin is effective in inhibiting the viability, invasion and migration of osteosarcoma cells and may be a promising candidate drug for the treatment of osteosarcoma. Further experiments are being undertaken to elucidate the possible mechanisms responsible for this phenomenon.
Alta sensibilidade da vigilância da tuberculose no sistema de vigilância nacional integrado na Finlândia
Authors: M Kokki, P Holmström, P Ruutu
Journal: Eurosurveillance (2005)

Existem poucos dados sobre a sensibilidade da vigilância da tuberculose na Finlândia desde a integracao em 1987 do sistema de vigilância e de controle especifico da doenca no sistema geral de saude. Foram comparadas as declaracoes em rotina de Mycobacterium tuberculosis realizadas pelos laboratorios ao Registro nacional das doencas infecciosas (National Infectious Disease Register, NIDR) entre o 1° de janeiro 1995 e o 31 de Dezembro 1996, com os dados recolhidos independentemente de todos os laboratorios que realizam cultivo de M. tuberculosis e com os dados dos registos medicos dos pacientes. Foram identificados 1059 casos com cultivo positivo. A sensibilidade global do NIDR era de 93% (984/1059). O valor predictivo positivo de um caso positivo por cultivo no NIDR de ser um verdadeiro caso confirmado por cultivo era de 99%. Quanto aos casos confirmados por cultivo no NIDR, 89% deles foram notificados por um ou varios medicos. Pode-se dispor de um sistema muito sensivel de notificacao dos casos de tuberculose confirmados por cultivo por meio de um sistema de vigilância integrado das doencas infecciosas basado nas declaracoes de laboratorios.
Engineering T-cells for adoptive cell therapy to overcome TGF-β-mediated immunosuppression in the tumour microenvironment
Authors: I. Catchpole, S. Brett, N. Sheppard, D Caballero Pradas, J. Jing, D. Steiner, D. Figueroa, L. Tsvetkov, Y. Katlinskaya, H. Kaczynski, R. Abbott, J. Silk, K. Adams, A. Gerry, A. Quattrini, B. Tavano, K. Crossland, G. Weiderman, T. Cornforth, C. Britten
Journal: Annals of Oncology (2017)
A Metabolic Interplay Coordinated By Hlx Balances Hematopoietic Stem Cell Maintenance and Differentiation
Authors: Eirini Trompouki, Indre Piragyte, Thomas Clapes, Ramon Klein-Geltnik, Na Yin, Aikaterini Polyzou, Xavier Langa Oliva, Cora Beckmann, Stylianos Lefkopoulos, Marcin W. Wlodarski, Dominic Van Essen, Angelika Rambold, Friedrich G Kapp, Marina Mione, Erika L. Pearce, Alexander Polyzos
Journal: Blood (2017)
Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.
Authors: José E. Alés-Martínez, Elena Filipovich, Juan Luis García Llano, Jaime Ceballos Viro, Ricardo Sánchez-Escribano
Journal: Journal of Clinical Oncology (2014)

e11513 Background: Two targeted agents, trastuzumab and lapatinib, enhance apoptosis in Her2-positive breast cancer cells. After progression to trastuzumab, the combination of lapatinib and capecitabine improves PFS and OS compared to capecitabine alone. Recent studies show benefit with trastuzumab continuation after progression. Also, combining trastuzumab and lapatinib or pertuzumab (double blockade) without chemotherapy has shown significant antitumor activity in metastatic and neoadjuvant settings. Finally, combining chemotherapy with double blockade has consistently shown better response rates in neoadjuvant trials than chemotherapy plus single blockade or double blockade without chemotherapy. We have started a program to treat patients progressing to prior trastuzumab regimen(s) with a combination of capecitabine, lapatinib and trastuzumab (CLT) in order to maximize Her2 blockade in combination with chemotherapy. Methods: All patients (5) were Her2+ infiltrating ductal carcinomas (ER+/PR-: 40%, ER-/PR+: 20%, ER-/PR-: 40%, median Ki67+ 65% (20-80%)) and were progressing after at least one prior trastuzumab containing regimen. Three of them had brain metastases. Trastuzumab was given at 6 mg/kg q3w in all except the first patient that was initiated at 2 mg/Kg until recovery of the performance status. Initial capecitabine dose was 1000 mg/m2/12h q3w and doses of lapatinib ranged between 750-1250 mg daily. Results: After a median 15 months follow-up (18, 8, 11, 15 and 28 months, respectively), 80% of the patients are still on treatment without progression and evident benefit in terms of response (2PR, 1 CR, 2SD) and clinical status. Dose reductions were needed in all patients for capecitabine due to PPE (grade I-II all episodes, one level reduction) and in one patient for lapatinib (initial dose 1250 mg/d) due to diarrhea GII. Median age: 49y (range 47-75y), median ECOG: 1 (0-2). Conclusions: After adjusting for individual tolerability, CLT is a very well tolerated regimen with an excellent efficacy in terms of response and PFS, reinforcing de value of providing double blockade plus chemotherapy to Her2+ metastatic patients.
Gene therapy with adeno-associated virus vector 5–human factor IX in adults with hemophilia B
Authors: Wolfgang Miesbach, Karina Meijer, Michiel Coppens, Peter Kampmann, Robert Klamroth, Roger Schutgens, Marco Tangelder, Giancarlo Castaman, Joachim Schwäble, Halvard Bonig, Erhard Seifried, Federica Cattaneo, Christian Meyer, Frank W. G. Leebeek
Journal: Blood (2017)
Surfactant protein D is a causal risk factor for COPD: results of Mendelian randomisation
Authors: Ma'en Obeidat, Xuan Li, Stephen Burgess, Guohai Zhou, Nick Fishbane, Nadia N. Hansel, Yohan Bossé, Philippe Joubert, Ke Hao, David C. Nickle, Maarten van den Berge, Wim Timens, Michael H. Cho, Brian D. Hobbs, Kim de Jong, Marike Boezen, Rayjean J. Hung, Nicholas Rafaels, Rasika Mathias, Ingo Ruczinski, Terri H. Beaty, Kathleen C. Barnes, Peter D. Paré, Don D. Sin
Journal: European Respiratory Journal (2017)

Surfactant protein D (SP-D) is produced primarily in the lung and is involved in regulating pulmonary surfactants, lipid homeostasis and innate immunity. Circulating SP-D levels in blood are associated with chronic obstructive pulmonary disease (COPD), although causality remains elusive.In 4061 subjects with COPD, we identified genetic variants associated with serum SP-D levels. We then determined whether these variants affected lung tissue gene expression in 1037 individuals. A Mendelian randomisation framework was then applied, whereby serum SP-D-associated variants were tested for association with COPD risk in 11 157 cases and 36 699 controls and with 11 years decline of lung function in the 4061 individuals.Three regions on chromosomes 6 (human leukocyte antigen region), 10 (SFTPD gene) and 16 (ATP2C2 gene) were associated with serum SP-D levels at genome-wide significance. In Mendelian randomisation analyses, variants associated with increased serum SP-D levels decreased the risk of COPD (estimate -0.19, p=6.46×10-03) and slowed the lung function decline (estimate=0.0038, p=7.68×10-3).Leveraging genetic variation effect on protein, lung gene expression and disease phenotypes provided novel insights into SP-D biology and established a causal link between increased SP-D levels and protection against COPD risk and progression. SP-D represents a very promising biomarker and therapeutic target for COPD.
Interaction Of Type 2 Cytotoxic T Lymphocytes And Mast Cell Lipid Mediators Contributes To Pathogenesis Of Eosinophilic Asthma
Authors: L Xue, L Stoeger, E Marchi, W Liu, S Go, A Kurioka, T Leng, M Salimi, R Shrimanker, T Powell, A Ramasamy, G Ogg, I Pavord, P Klenerman
Journal: American Journal of Respiratory and Critical Care Medicine (2017)
Selective internal radiation therapy (SIRT) promotes the recruitment of tumor-infiltrating lymphocytes and enhances cytotoxic activity in hepatocellular carcinoma
Authors: L. Craciun, R. De Wind, P. Demetter, V. Lucidi, S. Michiels, S. Garaud, C. Naveaux, M. Gomez Galdon, A. Hendlisz, K. Willard Gallo, P. Flamen, D. Larsimont, V. Donckier
Journal: Annals of Oncology (2017)